Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction

Dimitrios M. Konstantinou, Ioannis S Chatzizisis, George D. Giannoglou

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Heart failure has become increasingly prevalent and poses a significant socioeconomic burden in the developed world. Approximately half of heart failure patients have preserved ejection fraction (HFpEF) and experience an increased morbidity and mortality attributed to the lack of effective therapies and to the presence of comorbidities. Suppression of neurohormonal activation by beta-blockers and renin-angiotensin-aldosterone system inhibitors is the cornerstone in the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF). However, these medications are not associated with significant clinical benefit in HFpEF. In this review, we provide an in-depth pathophysiology-based update on novel pharmacotherapies of HFpEF. A deeper insight into the pathophysiologic mechanisms of HFpEF may create opportunities for novel pharmacological interventions.

Original languageEnglish (US)
Pages (from-to)156-166
Number of pages11
JournalPharmacology and Therapeutics
Volume140
Issue number2
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Heart Failure
Drug Therapy
Renin-Angiotensin System
Comorbidity
Pharmacology
Morbidity
Mortality
Therapeutics

Keywords

  • Diastolic dysfunction
  • Heart failure
  • Pathophysiology
  • Pharmacotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction. / Konstantinou, Dimitrios M.; Chatzizisis, Ioannis S; Giannoglou, George D.

In: Pharmacology and Therapeutics, Vol. 140, No. 2, 01.11.2013, p. 156-166.

Research output: Contribution to journalReview article

@article{418c9baa7b0e41da9fbc2d6e936d757f,
title = "Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction",
abstract = "Heart failure has become increasingly prevalent and poses a significant socioeconomic burden in the developed world. Approximately half of heart failure patients have preserved ejection fraction (HFpEF) and experience an increased morbidity and mortality attributed to the lack of effective therapies and to the presence of comorbidities. Suppression of neurohormonal activation by beta-blockers and renin-angiotensin-aldosterone system inhibitors is the cornerstone in the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF). However, these medications are not associated with significant clinical benefit in HFpEF. In this review, we provide an in-depth pathophysiology-based update on novel pharmacotherapies of HFpEF. A deeper insight into the pathophysiologic mechanisms of HFpEF may create opportunities for novel pharmacological interventions.",
keywords = "Diastolic dysfunction, Heart failure, Pathophysiology, Pharmacotherapy",
author = "Konstantinou, {Dimitrios M.} and Chatzizisis, {Ioannis S} and Giannoglou, {George D.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.pharmthera.2013.05.012",
language = "English (US)",
volume = "140",
pages = "156--166",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction

AU - Konstantinou, Dimitrios M.

AU - Chatzizisis, Ioannis S

AU - Giannoglou, George D.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Heart failure has become increasingly prevalent and poses a significant socioeconomic burden in the developed world. Approximately half of heart failure patients have preserved ejection fraction (HFpEF) and experience an increased morbidity and mortality attributed to the lack of effective therapies and to the presence of comorbidities. Suppression of neurohormonal activation by beta-blockers and renin-angiotensin-aldosterone system inhibitors is the cornerstone in the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF). However, these medications are not associated with significant clinical benefit in HFpEF. In this review, we provide an in-depth pathophysiology-based update on novel pharmacotherapies of HFpEF. A deeper insight into the pathophysiologic mechanisms of HFpEF may create opportunities for novel pharmacological interventions.

AB - Heart failure has become increasingly prevalent and poses a significant socioeconomic burden in the developed world. Approximately half of heart failure patients have preserved ejection fraction (HFpEF) and experience an increased morbidity and mortality attributed to the lack of effective therapies and to the presence of comorbidities. Suppression of neurohormonal activation by beta-blockers and renin-angiotensin-aldosterone system inhibitors is the cornerstone in the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF). However, these medications are not associated with significant clinical benefit in HFpEF. In this review, we provide an in-depth pathophysiology-based update on novel pharmacotherapies of HFpEF. A deeper insight into the pathophysiologic mechanisms of HFpEF may create opportunities for novel pharmacological interventions.

KW - Diastolic dysfunction

KW - Heart failure

KW - Pathophysiology

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84885173589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885173589&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2013.05.012

DO - 10.1016/j.pharmthera.2013.05.012

M3 - Review article

VL - 140

SP - 156

EP - 166

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 2

ER -